News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
The facility is among 12 centres established worldwide, and the first in Asia
Glenmark Pharmaceuticals won Innovation of the Year award
The minister was speaking at the 7th International conference on Pharma and Medical Devices sector; chairs two roundtable conferences with the CEOs
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
Subscribe To Our Newsletter & Stay Updated
